GLAXOSMITHKLINE PHARMA LT Valuation
GLAXO · Healthcare · Current price ₹2,932.1
Is GLAXOSMITHKLINE PHARMA LT undervalued?
DocStoX estimates the fair value of GLAXOSMITHKLINE PHARMA LT at ₹1,391 per share, versus the current market price of ₹2,932. That puts the stock about -52.6% above our fair-value estimate, which we read as "Avoid". Our confidence in this estimate is low.
How this fair value is calculated
This estimate blends 4 independent methods: Residual income (₹500), Relative P/E (₹2,392), Graham floor (₹429), Analyst target (₹3,081). We weight each by its reliability and skip any method whose inputs look untrustworthy — "no DCF beats a wrong DCF". This is the same deterministic engine that powers DocStoX stock pages; there is no guesswork or AI-generated number here.
Bear, base and bull scenarios
Our scenarios span ₹429 (bear) to ₹1,391 (base) to ₹3,081 (bull). A margin of safety means buying meaningfully below the base case — the wider the gap, the more room for error in the assumptions.
Valuation multiples
GLAXOSMITHKLINE PHARMA LT trades at a P/E of 48.0x and a P/B of 18.3x, with a dividend yield of 1.9%. Multiples are most useful compared against the company's own history and its sector peers — see the peer comparison for context.
Understand the ratios
More on GLAXOSMITHKLINE PHARMA LT
DocStoX estimates are generated by a deterministic valuation engine from reported financials — for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.